June 2020
Volume 61, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2020
Transgene Expression in RPE and Retina after Suprachoroidal delivery of AAV vectors
Author Affiliations & Notes
  • Kun Ding
    Wilmer Eye Institute, Baltimore, Maryland, United States
  • Jikui Shen
    Wilmer Eye Institute, Baltimore, Maryland, United States
  • Sean Hackett
    Wilmer Eye Institute, Baltimore, Maryland, United States
  • Peter A Campochiaro
    Wilmer Eye Institute, Baltimore, Maryland, United States
  • Footnotes
    Commercial Relationships   Kun Ding, None; Jikui Shen, None; Sean Hackett, None; Peter Campochiaro, Aerpio Pharmaceuticals (I), Allegro (I), Applied Genetic Technologies Corporation (I), Asclepix Therapeutices (F), Exonate Ltd. (I), Genetech/Roche Inc. (F), Graybug Vision (F), Merck & Co. (I), Novartis Pharmaceuticals (I), Oxford Biomedica (F), Perfuse (I), Sanofi/Genezyme (F), Wave Life Sciences (I)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 4490. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kun Ding, Jikui Shen, Sean Hackett, Peter A Campochiaro; Transgene Expression in RPE and Retina after Suprachoroidal delivery of AAV vectors. Invest. Ophthalmol. Vis. Sci. 2020;61(7):4490.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Suprachoroidal gene transfer provides a new noninvasive approach and we have previously demonstrated widespread expression in photoreceptors and RPE after suprachoroidal injection of AAV8.GFP and AAV9.GFP, but not AAV2.GFP. This study was designed to assess the expression of AAV2tYF and AAV5 vectors after suprachoroidal injection.

Methods : Norway Brown rats (n=65) had suprachoroidal injection of 7.8 x 109 GC of AAV2tYF-CBA-hGFP, 7.8 x 109 GC of AAV2tYF-GRK1-hGFP, 7.8 x 109 GC of AAV5-GRK1-hGFP, or 6.87 x 109 GC of AAV2-CBA-hGFP. At 2 or 4 weeks after injection, retina and RPE/choroid flat mounts or ocular sections were examined by fluorescence microscopy. Homogenates of RPE/choroid and retinas were used to measure total protein and GFP protein was measured by ELISA.

Results : Each of the vectors reached peak expression by 2 weeks after injection except AAV2tYF-GRK1-hGFP which showed some further increase between 2 and 4 weeks. Compared with AAV2-CBA-hGFP, AAV2tYF-CBA-hGFP showed more extensive and higher expression of GFP, extending approximately 1/4 circumference of the eye in the RPE and all layers of the retina. Expression was limited to photoreceptors (inner segments, outer segments and some cell bodies) after suprachoroidal injection of AAV2tYF-GRK1-GFP and AAV5tYF-GRK1-GFP, and extending around 1/4 and 1/6 the circumference of the eye, respectively. The mean (± SEM) level of GFP (ng/mg protein) in retina for each of the vectors is shown in Table 1.

Conclusions : AAV2tYF-CBA provides much greater transduction after suprachoroidal injection than AAV2-CBA. The extent of expression is less than that previously seen with AAV8 and AAV9, but provides more transduction of inner retinal cells. Compared with AAV5-GRK1, AAV2tYF-GRK1 provides greater and more extensive transduction of photoreceptors.

This is a 2020 ARVO Annual Meeting abstract.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×